ES2055735T3 - Agentes citotoxicos con longitud de onda especifica. - Google Patents

Agentes citotoxicos con longitud de onda especifica.

Info

Publication number
ES2055735T3
ES2055735T3 ES88300409T ES88300409T ES2055735T3 ES 2055735 T3 ES2055735 T3 ES 2055735T3 ES 88300409 T ES88300409 T ES 88300409T ES 88300409 T ES88300409 T ES 88300409T ES 2055735 T3 ES2055735 T3 ES 2055735T3
Authority
ES
Spain
Prior art keywords
treatment
wave length
cytotoxic agents
specific wave
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88300409T
Other languages
English (en)
Inventor
Julia G Levy
David Dolphin
Jack K Chow
Ethan Sternberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2055735T3 publication Critical patent/ES2055735T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN GRUPO DE HIDRO-MONOBENZOPORFIRINAS "PORFIRINAS VERDES" (GP), QUE TIENEN MAXIMOS DE ABSORCION EN EL INTERVALO DE 670-720 NM, ES UTIL PARA EL TRATAMIENTO DE DESORDENES QUE ESTAN EXPUESTOS A TRATAMIENTO POR DERIVADOS DE HEMATOPORFIRINA (HPD) EN PRESENCIA DE LA LUZ. EL USO DE LAS GP DE LA INVENCION PERMITE LA IRRADIACION A OTRAS LONGITUDES DE ONDA QUE LAS ABSORBIDAS POR LA SANGRE. LAS GP DE LA INVENCION TAMBIEN SE PUEDEN CONJUGAR A LIGANDOS RECEPTORES O A INMUNOGLOBULINAS ESPECIFICAS O SUS FRAGMENTOS O TEJIDOS ESPECIFICOS BLANCO O CELULAS PARA EL TRATAMIENTO DE LA RADIACION. EL USO DE ESTOS MATERIALES PERMITE QUE SE UTILICEN NIVELES DE DROGA MAS BAJOS, EVITANDO ASI REACCIONES LATERALES QUE PUEDEN DESTRUIR TEJIDOS NORMALES.
ES88300409T 1987-01-20 1988-01-19 Agentes citotoxicos con longitud de onda especifica. Expired - Lifetime ES2055735T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US520487A 1987-01-20 1987-01-20
US07/041,680 US4883790A (en) 1987-01-20 1987-04-23 Wavelength-specific cytotoxic agents

Publications (1)

Publication Number Publication Date
ES2055735T3 true ES2055735T3 (es) 1994-09-01

Family

ID=26674064

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88300409T Expired - Lifetime ES2055735T3 (es) 1987-01-20 1988-01-19 Agentes citotoxicos con longitud de onda especifica.

Country Status (7)

Country Link
US (1) US4883790A (es)
EP (1) EP0276121B1 (es)
JP (2) JPH068319B2 (es)
AU (1) AU618725B2 (es)
CA (1) CA1333442C (es)
DE (1) DE3889231T2 (es)
ES (1) ES2055735T3 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5109129A (en) * 1989-09-29 1992-04-28 The University Of Toledo, Medical College Of Ohio Porphyrin derivatives
CA1341460C (en) * 1988-01-11 2004-10-19 The Medical College Of Ohio Production and use of porphyrin derivatives and of compositions containing such derivates
US5198460A (en) * 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
USRE39094E1 (en) * 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
US4979935A (en) * 1989-02-21 1990-12-25 Quantex Corporation Method of photodynamic therapy employing electron trapping material
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5162509A (en) * 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5567687A (en) * 1989-03-06 1996-10-22 University Of Texas Texaphyrins and uses thereof
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5041078A (en) * 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5272142A (en) * 1989-03-06 1993-12-21 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US5256399A (en) * 1989-03-06 1993-10-26 Board Of Regents, The University Of Texas System Aromatic pentadentate expanded porphyrins in magnetic resonance imaging
EP0476011A1 (en) * 1989-06-07 1992-03-25 The University Of British Columbia Photosensitizing diels-alder porphyrin derivatives
US5308608A (en) * 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5457195A (en) * 1989-12-21 1995-10-10 Board Of Regents, The University Of Texas System Sapphyrin derivatives and conjugates
US5120411A (en) * 1989-12-21 1992-06-09 Board Of Regents, The University Of Texas System Photodynamic activity of sapphyrins
US5543514A (en) * 1989-12-21 1996-08-06 Board Of Regents, The University Of Texas System Water-soluble sapphyrins
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
US5159065A (en) * 1989-12-21 1992-10-27 Board Of Regents, The University Of Texas System Sapphyrins, derivatives and syntheses
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5238940A (en) * 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5354858A (en) * 1991-03-28 1994-10-11 The University Of Toledo Production and use of Diels Alder adducts of vinyl porphyrins and of compositions containing such adducts
US5563262A (en) * 1991-03-28 1996-10-08 University Of Toledo Diels alder adducts of vinyl porphyrins
US5587394A (en) * 1991-03-28 1996-12-24 The University Of Toledo Production and use of diels alder adducts of vinyl porphyrins, of metal complexes thereof, and of compositions containing such adducts and complexes
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
EP0601183A4 (en) * 1991-08-02 1996-12-04 Meiji Milk Prod Co Ltd ANTI-HIV MEDICINE.
US5595726A (en) * 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US5410045A (en) * 1992-08-04 1995-04-25 Board Of Regents, The University Of Texas System Rubyrin and related expanded porphyrins
EP0654993A1 (en) * 1992-08-17 1995-05-31 Quadra Logic Technologies Inc. Method for destroying or inhibiting growth of unwanted cells or tissues
US5798491A (en) * 1993-06-09 1998-08-25 Board Of Regents, The University Of Texas System Multi-mechanistic chemical cleavage using certain metal complexes
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
US5837866A (en) * 1994-09-21 1998-11-17 Board Of Regents, The University Of Texas Phosphoramidite derivatives of macrocycles
US5633354A (en) * 1994-09-21 1997-05-27 Pharmacyclics, Inc. Phosphoramidite derivatives of texaphyrins
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
WO1999013943A1 (en) 1996-03-05 1999-03-25 Ekos Corporation Ultrasound assembly for use with light activated drugs
EP0983273B8 (en) 1997-05-07 2002-10-09 QLT Inc. Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
US5880145A (en) * 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
JP3907212B2 (ja) * 1997-05-07 2007-04-18 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 新規なクラスのベンゾポルフィリン誘導体光活性化合物
AU4278400A (en) * 1999-04-14 2000-11-14 University Of British Columbia, The Improved beta,beta,-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
UA75350C2 (en) * 2000-03-24 2006-04-17 Novartis Ag Method for photodynamic treatment of undesirable subfoveal choroidal neovascularization using antiangiogenic agent
CA2408332C (en) 2000-05-08 2011-02-15 The University Of British Columbia Supports for photosensitizer formulations
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
AU2002348477A1 (en) * 2001-05-01 2002-12-23 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
AU2002336867A1 (en) * 2001-11-02 2003-05-12 Qlt Inc. Micelle compositions containing pegylated phospholipids and a photosensitizer
EP1443964B1 (en) * 2001-11-09 2008-02-20 QLT Inc. Photodynamic therapy for the treatment of hair loss
US7455858B2 (en) * 2002-05-16 2008-11-25 Qlt Inc. Compositions and methods for delivery of photosensitive drugs
US7175611B2 (en) 2002-06-05 2007-02-13 Mark Alan Mitchnick Antimicrobial release system
WO2004099375A2 (en) * 2003-04-30 2004-11-18 The General Hospital Corporation Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use therof
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2437638A1 (en) * 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
JP2008515800A (ja) * 2004-10-04 2008-05-15 セルゲイト， インコーポレイテッド 眼科疾患の処置剤としてのポリアミン類似化合物
DE102005015286A1 (de) * 2005-04-04 2006-10-05 Tetrapdt Gmbh Photosensibilisatoren als Arzneimittelträger für lokale Markierung und Therapie von neoplastischem Gewebe
ES2699376T3 (es) 2008-05-05 2019-02-11 Massachusetts Gen Hospital Métodos para usar sustratos enzimáticos marcados con bodipy
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US20110118600A1 (en) 2009-11-16 2011-05-19 Michael Gertner External Autonomic Modulation
MX2013008175A (es) 2011-01-13 2013-12-16 Quadra Logic Tech Inc Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
EP2521593B1 (en) 2011-03-15 2015-12-09 Kona Medical, Inc. Energetic modulation of nerves
CA2878846A1 (en) 2012-07-11 2014-01-16 Delphine Caroline Imbert Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
CA3056396A1 (en) 2017-03-14 2018-09-20 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951800A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes utilizing improved catalysts
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates

Also Published As

Publication number Publication date
EP0276121B1 (en) 1994-04-27
AU1038888A (en) 1988-07-21
CA1333442C (en) 1994-12-06
EP0276121A2 (en) 1988-07-27
JP2835294B2 (ja) 1998-12-14
US4883790A (en) 1989-11-28
JPS63277700A (ja) 1988-11-15
JPH068319B2 (ja) 1994-02-02
AU618725B2 (en) 1992-01-09
DE3889231T2 (de) 1994-08-11
DE3889231D1 (de) 1994-06-01
EP0276121A3 (en) 1989-10-18
JPH07258262A (ja) 1995-10-09

Similar Documents

Publication Publication Date Title
ES2055735T3 (es) Agentes citotoxicos con longitud de onda especifica.
ES2080745T3 (es) Agentes citotoxicos de longitud de onda especifica
ZA906664B (en) Laser light irradiation apparatus
ES2099098T3 (es) Dispositivo para irradiar rayos laser.
ES2073583T3 (es) Dispositivo para irradiar rayos laser.
SE9500285D0 (sv) Pin Plate
FR2640537B1 (fr) Installation et procede utilisant l'effet laser, pour la coupe ou la vaporisation de materiaux et tissus divers
DE69010840D1 (de) Sterile chirurgische Nadel-Nähfaden-Zusammensetzung.
AR019308A1 (es) Formulaciones de particulas novedosas.
ES2058775T3 (es) Dispositivos de dispensacion impulsados por hidrogel.
ES2027763T3 (es) Cemento oseo para la liberacion controlada de sustancias.
ES2019920B3 (es) Procedimiento para combatir los hongos
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
ES2090131T3 (es) Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas.
PT916306E (pt) Dispositivo para exame estereoscopico do olho de um paciente
DK0467026T3 (da) Middel til farvning af hår og anvendelse af midlet
ES2047014T3 (es) Procedimiento para preparar un catalizador basado en plata y procedimiento para epoxidar olefinas superiores.
ES2051733T3 (es) Procedimiento de obtencion de un medicamento a base de tamoxifen para uso local.
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
AU778495B2 (en) Tissue rejuvenation by illuminating radiation
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
SU1007659A1 (ru) Фиксатор дл компрессионного остеосинтеза
JPH01141671A (ja) レーザ光照射医療装置
RU97113796A (ru) Способ лазеротерапии при лечении переломов трубчатой кости

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 276121

Country of ref document: ES